Laura Campo is Chair of the EFPIA Alzheimer's Disease Platform and Executive Director, International Corporate Affairs, Alzheimer’s disease at Eli Lilly and Company.

Laura Campo is responsible for the out-of-US relationships with Patient Associations and Health Professionals in the Global Corporate Affairs division at Eli Lilly and Company. In her role, Laura coordinates Lilly’s efforts to engage the external environment in Alzheimer’s disease.

Before joining the International Corporate Affairs role, Laura served as Corporate Affairs Market Access Manager at Eli Lilly Italia, supporting the Regional access plans in the Oncology, Cardiovascular, CNS, and other therapeutic areas, with a special focus on the partnership programs with Regional Institutions on the optimization of NHS processes.

During the years in the Italian Corporate Affairs Division, Laura also covered the role of Country Leader for two major Lilly efforts in the environment engagement space, raising the attention to public policy issues that limit the access to patient’s care in the Oncology area and in the Alzheimer’s disease area.

In the previous years within Eli Lilly and Company, Laura covered other National and International roles as Marketing Manager in the Attention Deficit & Hyperactivity Disorder area in Lilly Italia, European Regulatory Affairs Manager in the UK and Research Scientist in the Lilly Research Laboratories (Indianapolis).

Laura pursued a post-doctoral fellowship at the University of Alabama at Birmingham and her graduate school in Italy where she currently lives.